210 related articles for article (PubMed ID: 34429509)
1. Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2.
Novoyatleva T; Rai N; Kojonazarov B; Veeroju S; Ben-Batalla I; Caruso P; Shihan M; Presser N; Götz E; Lepper C; Herpel S; Manaud G; Perros F; Gall H; Ghofrani HA; Weissmann N; Grimminger F; Wharton J; Wilkins M; Upton PD; Loges S; Morrell NW; Seeger W; Schermuly RT
Commun Biol; 2021 Aug; 4(1):1002. PubMed ID: 34429509
[TBL] [Abstract][Full Text] [Related]
2. CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
Nie X; Tan J; Dai Y; Liu Y; Zou J; Sun J; Ye S; Shen C; Fan L; Chen J; Bian JS
J Mol Cell Cardiol; 2018 Mar; 116():41-56. PubMed ID: 29374556
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension.
Bisserier M; Katz MG; Bueno-Beti C; Brojakowska A; Zhang S; Gubara S; Kohlbrenner E; Fazal S; Fargnoli A; Dorfmuller P; Humbert M; Hata A; Goukassian DA; Sassi Y; Hadri L
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502015
[TBL] [Abstract][Full Text] [Related]
4. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.
Meloche J; Courchesne A; Barrier M; Carter S; Bisserier M; Paulin R; Lauzon-Joset JF; Breuils-Bonnet S; Tremblay É; Biardel S; Racine C; Courture C; Bonnet P; Majka SM; Deshaies Y; Picard F; Provencher S; Bonnet S
J Am Heart Assoc; 2013 Jan; 2(1):e005157. PubMed ID: 23525442
[TBL] [Abstract][Full Text] [Related]
5. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.
Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR
Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075
[TBL] [Abstract][Full Text] [Related]
6. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
Cheng G; Wang X; Li Y; He L
Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784
[TBL] [Abstract][Full Text] [Related]
7. Endothelial
Theilmann AL; Hawke LG; Hilton LR; Whitford MKM; Cole DV; Mackeil JL; Dunham-Snary KJ; Mewburn J; James PD; Maurice DH; Archer SL; Ormiston ML
Arterioscler Thromb Vasc Biol; 2020 Nov; 40(11):2605-2618. PubMed ID: 32998516
[TBL] [Abstract][Full Text] [Related]
8. Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension.
Morty RE; Nejman B; Kwapiszewska G; Hecker M; Zakrzewicz A; Kouri FM; Peters DM; Dumitrascu R; Seeger W; Knaus P; Schermuly RT; Eickelberg O
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1072-8. PubMed ID: 17347486
[TBL] [Abstract][Full Text] [Related]
9. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
Long L; Crosby A; Yang X; Southwood M; Upton PD; Kim DK; Morrell NW
Circulation; 2009 Feb; 119(4):566-76. PubMed ID: 19153267
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.
McMurtry MS; Moudgil R; Hashimoto K; Bonnet S; Michelakis ED; Archer SL
Am J Physiol Lung Cell Mol Physiol; 2007 Apr; 292(4):L872-8. PubMed ID: 17142350
[TBL] [Abstract][Full Text] [Related]
11. Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension.
Yang J; Li X; Al-Lamki RS; Wu C; Weiss A; Berk J; Schermuly RT; Morrell NW
Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):34-42. PubMed ID: 23139294
[TBL] [Abstract][Full Text] [Related]
12. Impaired Interleukin-15 Signaling via
Hilton LR; Rätsep MT; VandenBroek MM; Jafri S; Laverty KJ; Mitchell M; Theilmann AL; Smart JA; Hawke LG; Moore SD; Renaud SJ; Soares MJ; Morrell NW; Ormiston ML
Hypertension; 2022 Nov; 79(11):2493-2504. PubMed ID: 36043416
[TBL] [Abstract][Full Text] [Related]
13. The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient.
Happé C; Kurakula K; Sun XQ; da Silva Goncalves Bos D; Rol N; Guignabert C; Tu L; Schalij I; Wiesmeijer KC; Tura-Ceide O; Vonk Noordegraaf A; de Man FS; Bogaard HJ; Goumans MJ
Cells; 2020 Jun; 9(6):. PubMed ID: 32521690
[No Abstract] [Full Text] [Related]
14. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.
Long L; Ormiston ML; Yang X; Southwood M; Gräf S; Machado RD; Mueller M; Kinzel B; Yung LM; Wilkinson JM; Moore SD; Drake KM; Aldred MA; Yu PB; Upton PD; Morrell NW
Nat Med; 2015 Jul; 21(7):777-85. PubMed ID: 26076038
[TBL] [Abstract][Full Text] [Related]
15. Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension.
Gomez-Puerto MC; van Zuijen I; Huang CJ; Szulcek R; Pan X; van Dinther MA; Kurakula K; Wiesmeijer CC; Goumans MJ; Bogaard HJ; Morrell NW; Rana AA; Ten Dijke P
J Pathol; 2019 Nov; 249(3):356-367. PubMed ID: 31257577
[TBL] [Abstract][Full Text] [Related]
16. PPARγ-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension.
Hennigs JK; Cao A; Li CG; Shi M; Mienert J; Miyagawa K; Körbelin J; Marciano DP; Chen PI; Roughley M; Elliott MV; Harper RL; Bill MA; Chappell J; Moonen JR; Diebold I; Wang L; Snyder MP; Rabinovitch M
Circ Res; 2021 Feb; 128(3):401-418. PubMed ID: 33322916
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension.
Bisserier M; Mathiyalagan P; Zhang S; Elmastour F; Dorfmüller P; Humbert M; David G; Tarzami S; Weber T; Perros F; Sassi Y; Sahoo S; Hadri L
Circulation; 2021 Jul; 144(1):52-73. PubMed ID: 34078089
[TBL] [Abstract][Full Text] [Related]
18. Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
Wang Y; Zhang XH; Wang HL
Can J Physiol Pharmacol; 2011 May; 89(5):345-54. PubMed ID: 21619414
[TBL] [Abstract][Full Text] [Related]
19. Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo.
Yang J; Li X; Al-Lamki RS; Southwood M; Zhao J; Lever AM; Grimminger F; Schermuly RT; Morrell NW
Circ Res; 2010 Jul; 107(2):252-62. PubMed ID: 20522807
[TBL] [Abstract][Full Text] [Related]
20. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.
Spiekerkoetter E; Tian X; Cai J; Hopper RK; Sudheendra D; Li CG; El-Bizri N; Sawada H; Haghighat R; Chan R; Haghighat L; de Jesus Perez V; Wang L; Reddy S; Zhao M; Bernstein D; Solow-Cordero DE; Beachy PA; Wandless TJ; Ten Dijke P; Rabinovitch M
J Clin Invest; 2013 Aug; 123(8):3600-13. PubMed ID: 23867624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
